NEW YORK (GenomeWeb News) – Cancer Genetics has again lowered the amount it expects to bring in from its pending initial public offering, the Rutherford, NJ-based firm disclosed in a document filed with the US Securities and Exchange Commission late on Wednesday.
The cancer diagnostics company said that it now plans to offer 5 million shares of its common stock in an IPO at a share price of between $4 and $6. At the $5 midpoint, the offering would bring in $20.1 million in net proceeds, it said. The amount would rise to $23.5 million if the underwriters of the offering exercise their overallotment options in full.
Cancer Genetics initially filed for an IPO in December 2011, hoping to raise $48.6 million in net proceeds, then lowered that figure to $34.2 million. The underwriters of the offering have also changed since Cancer Genetics filed its Form S-1 more than a year ago. Aegis Capital is now listed as the sole book-running manager and Feltl & Co. is the co-manager.
The company's shares would be trade on the Nasdaq under ticker symbol "CGIX," upon approval.
Its management team includes CEO Panna Sharma, Chairman Raju Chaganti, and CFO Elizabeth Czerepak.
With the expected lower proceeds, the company on Wednesday also revised how the funds would be used. It said about $3.5 million would go to repay "certain outstanding indebtedness," while $5.0 million would fund R&D, potential regulatory submissions, and potential product launches and collaborations.
About $7.0 million would be directed at hiring sales and marketing staff, and $2.0 million would go toward funding the company's joint venture with the Mayo Foundation for Medical Education and Research to develop oncology diagnostic services and tests using next-generation sequencing. Remaining net proceeds would be for ongoing operations and business expansion.
Cancer Genetics recorded $3.2 million in revenues through the first nine months of 2012, compared to $2.1 million in the year-ago period, it said. Its net loss in the first nine months of 2012 dropped to $2.6 million, or $2.66 per share, from a net loss of $16.8 million, or $5.30 per share, in the year-ago period.
On a pro forma basis, its net loss was $1.12 per share for the first three quarters of 2012, compared to a net loss of $2.54 per share in the corresponding year-ago period.
Its R&D expenses rose to $1.6 million from $1.4 million, while its SG&A costs inched up to $4.5 million from $4.4 million.